What are ADC's

Our services

ADC Review
is made possible by:

NCT01800695 (Clinical Trial / ABT-414)

Study Title
Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme (NCT01800695)

Trial Description
This study is evaluating the safety and pharmacokinetics of ABT-414 in subjects with glioblastoma multiforme. [1]

This trial is sponsored by AbbVie.

Study Data

  • Condition: Glioblastoma Multiforme
  • Interventions:
    • Drugs used in this trial
      • ABT-414
      • Temozolomide (Temodar®; Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.)
      • Radiation: Whole Brain Radiation
  • Phase: I
  • Estimated Enrollment: 202
  • Start: April 2013
  • Estimated Completion: June 2017
  • Last Verified: July 2017

Study Schematic 


Return to drug map

Last Editorial review: August 28, 2017
Information based on (NIH/NCI) and other sources.

Copyright © 2015-2017 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.



Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...

Skip to toolbar